Literature DB >> 1613662

Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

J Li1, C I Lord, W Haseltine, N L Letvin, J Sodroski.   

Abstract

Replication competent chimeric viruses that express the gag and pol proteins of SIVmac and the env proteins of HIV-1 were made. One such chimeric virus, SHIV-4, that expresses the vif, vpx, vpr, and nef regulatory genes of SIV and the tat and rev regulatory genes of HIV-1 replicated efficiently in cynomolgus monkeys. This model system can be used to evaluate the efficacy of anti-HIV-1 vaccines directed at the envelope glycoproteins, anti-HIV-1 envelope glycoprotein antiserum or monoclonal antibodies, and anti-HIV-1 drugs designed to inhibit the tat, rev, or env functions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613662

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  101 in total

1.  Structural, functional, and genetic comparisons of Epstein-Barr virus nuclear antigen 3A, 3B, and 3C homologues encoded by the rhesus lymphocryptovirus.

Authors:  H Jiang; Y G Cho; F Wang
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Pathogenic simian/human immunodeficiency virus SHIV(KU) inoculated into immunized macaques caused infection, but virus burdens progressively declined with time.

Authors:  P S Silverstein; G A Mackay; S Mukherjee; Z Li; M Piatak; J D Lifson; O Narayan; A Kumar
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Simian-human immunodeficiency virus containing a human immunodeficiency virus type 1 subtype-E envelope gene: persistent infection, CD4(+) T-cell depletion, and mucosal membrane transmission in macaques.

Authors:  S Himathongkham; N S Halpin; J Li; M W Stout; C J Miller; P A Luciw
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

4.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD+ T-cell depletion in macaques infected by a simian-human immunodeficiency virus.

Authors:  B Etemad-Moghadam; D Rhone; T Steenbeke; Y Sun; J Manola; R Gelman; J W Fanton; P Racz; K Tenner-Racz; M K Axthelm; N L Letvin; J Sodroski
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 6.  Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility.

Authors:  Megan K Patrick; James B Johnston; Christopher Power
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

7.  Spontaneous production of RANTES and antigen-specific IFN-gamma production in macaques vaccinated with SHIV-4 correlates with protection against SIVsm challenge.

Authors:  R K S Ahmed; B Makitalo; K Karlen; C Nilsson; G Biberfeld; R Thorstensson
Journal:  Clin Exp Immunol       Date:  2002-07       Impact factor: 4.330

8.  Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.

Authors:  Jeffrey D Lifson; Nancy L Haigwood
Journal:  Cold Spring Harb Perspect Med       Date:  2012-06       Impact factor: 6.915

Review 9.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

10.  Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors.

Authors:  K Uberla; C Stahl-Hennig; D Böttiger; K Mätz-Rensing; F J Kaup; J Li; W A Haseltine; B Fleckenstein; G Hunsmann; B Oberg
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.